El Perú (MX)
{name}
{subtitle}
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
city
~8 mi. (Torreón, Mexico, +192 more cities)
facility
Centro de Investigación Clínica de Alta Especialidad
biomarker
ER Positive, +1 more biomarker
condition
Breast Carcinoma
drug
abemaciclib, +1 more drug
drug type
hormone therapy, +1 more type
A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread
city
~8 mi. (Torreón, Mexico, +84 more cities)
facility
Local Institution
condition
Clear Cell Renal Cell Carcinoma
drug
nivolumab, +1 more drug
drug type
immunotherapy, +1 more type
Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)
city
~8 mi. (Torreón, Mexico, +137 more cities)
facility
Centro de Investigación Clínica de Alta Especialidad ( Site 0715)
condition
Skin Squamous Cell Carcinoma
drug
pembrolizumab
drug type
immunotherapy
Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)
city
~97 mi. (Madero, Mexico, +115 more cities)
facility
Centro de Estudios de Investigacion Metabolicos y Cardiovasculares ( Site 3101)
biomarker
ATM Loss, +27 more biomarkers
condition
Breast Carcinoma, +2 more conditions
drug
olaparib, +1 more drug
drug type
immunotherapy, +1 more type